NDT Advance Access originally published online on February 19, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrol Dial Transplant (2004) 19: 1142-1148
Nephrol Dial Transplant Vol. 19 No. 5 © ERA-EDTA 2004; all rights reserved
Original Article
Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate
Department of Nephrology, University Medical Center St Radboud, Nijmegen, The Netherlands
Correspondence and offprint requests to: Peggy W. G. du Buf-Vereijken, UMC St Radboud, Department of Nephrology, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Email: P.duBuf{at}nier.umcn.nl
Background. Patients with idiopathic membranous nephropathy (iMN) and renal insufficiency have a high risk for progression to end-stage renal disease (ESRD). In the short term, treatment with oral cyclophosphamide and steroids attenuates the deterioration of renal function in these patients; however, the long-term efficacy is unknown.
Methods. We have studied prospectively 65 patients with iMN and renal insufficiency (serum creatinine >135 µmol/l) who were treated with oral cyclophosphamide (1.5–2.0 mg/kg/day for 12 months) and steroids (methylprednisolone pulses 3 x 1 g, i.v. at months 1, 3 and 5, and oral prednisone 0.5 mg/kg/48 h for 6 months).
Results. Follow-up was 51 (5–132) months. Renal function temporarily improved or stabilized in all patients. A partial remission (PR) occurred in 56 patients followed by a complete remission (CR) in 17. During follow-up, 11 patients had relapsed (28% relapse rate after 5 years), of whom nine were re-treated because of renal function deterioration. At the end of follow-up, 16 patients were in CR, 31 in PR, eight had a persistent nephrotic syndrome, one had mild proteinuria, four had progressed to ESRD and five had died. Overall renal survival was 86% after 5 years and 74% after 7 years, compared with 32% after 5 and 7 years in a historical control group. Treatment-related complications occurred in two-thirds of patients, mainly consisting of bone marrow depression and infections. One patient has developed bladder cancer, another patient prostate cancer.
Conclusions. Renal survival is good if patients with iMN and renal insufficiency are treated with oral cyclophosphamide. However, side effects occur frequently and relapse rate is high during longer follow-up.
Keywords: cyclophosphamide; immunosuppressive therapy; kidney failure; membranous nephropathy; nephrotic syndrome; prednisone; proteinuria
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Eriguchi, H. Oka, T. Mizobuchi, T. Kamimura, K. Sugawara, and A. Harada Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3082 - 3088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hofstra, A. J. W. Branten, J. J. J. M. Wirtz, T. C. Noordzij, P. W. G. du Buf-Vereijken, and J. F. M. Wetzels Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial Nephrol. Dial. Transplant., August 8, 2009; (2009) gfp390v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hofstra and J. F. M. Wetzels Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the Netherlands Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3534 - 3538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hofstra, J. K. J. Deegens, E. J. Steenbergen, and J. F. M. Wetzels Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3160 - 3165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Senthil Nayagam, A. Ganguli, M. Rathi, H. S. Kohli, K. L. Gupta, K. Joshi, V. Sakhuja, and V. Jha Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1926 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Fervenza, S. Sethi, and U. Specks Idiopathic Membranous Nephropathy: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 905 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ballarin, R. Poveda, J. Ara, L. Perez, F. Calero, J. M. Grinyo, and R. Romero Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3196 - 3201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Jha, A. Ganguli, T. K. Saha, H. S. Kohli, K. Sud, K. L. Gupta, K. Joshi, and V. Sakhuja A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1899 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. G. du Buf-Vereijken and J. F. M. Wetzels Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency Nephrol. Dial. Transplant., February 1, 2006; 21(2): 389 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cattran Management of Membranous Nephropathy: When and What for Treatment J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1188 - 1194. [Full Text] [PDF]
|
|
|
|
|
|
A. J.W. Branten, P. W. du Buf-Vereijken, I. S. Klasen, F. H. Bosch, G. W. Feith, D. A. Hollander, and J. F. Wetzels Urinary Excretion of {beta}2-Microglobulin and IgG Predict Prognosis in Idiopathic Membranous Nephropathy: A Validation Study J. Am. Soc. Nephrol., January 1, 2005; 16(1): 169 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. G. du Buf-Vereijken and J. F. M. Wetzels Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2036 - 2043. [Abstract] [Full Text] [PDF]
|
|